Basic Information
| LncRNA/CircRNA Name | CASC19 |
| Synonyms | CARLO6, CARLo-6, LINC01245 |
| Region | GRCh38_8:127072694-127227541 |
| Ensemble | ENSG00000254166 |
| Refseq | NR_120364 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | gastric cancer |
| ICD-0-3 | C16 |
| Methods | qPCR, other |
| Sample | GC cell lines (AGS, BGC-823, MGC-803, HGC-27) |
| Expression Pattern | up-regulated |
| Function Description | CASC19 was upregulated in AGC clinical samples and was significantly associated with higher pathologic TNM stage, pathologic T stage, lymph node metastasis, and poor overall survival. Multivariable Cox analysis confirmed that CASC19 overexpression is an independent prognostic factor for overall survival. Furthermore, quantitative real-time PCR assay confirmed that CASC19 expression in four human gastric cancer cells (AGS, BGC-823, MGC-803, and HGC-27) was significantly upregulated compared with human normal gastric mucosal epithelial cell line (GES-1). Functionally, CASC19 knockdown inhibited GC cell proliferation and migration in vitro. |
| Pubmed ID | 31422382 |
| Year | 2019 |
| Title | Long Non-Coding RNA CASC19 Is Associated With the Progression and Prognosis of Advanced Gastric Cancer |
External Links
| Links for CASC19 | GenBank HGNC NONCODE |
| Links for gastric cancer | OMIM COSMIC |